trial

Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness

NCTId NCT04011280
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 39 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2022-03-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
39 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2019-08-12
Primary completion
2022-03-04
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
Varenicline

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
Veterans Medical Research FoundationCollaborator
University of California Riverside at C.I. Trials, Inc.-Inland EmpireCollaborator

Sites

1 total
La Jolla, United States

Facts & assertions

4 sourced
Enrollment
39
Phase
PHASE4
Primary Completion Date
2022-03-04
Status
COMPLETED
relationships
The graph out of here
drug
Varenicline
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
Veterans Medical Research Foundation
company
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Nicotine Dependence
indication
Bipolar Disorder
indication
Tobacco Use Disorder
indication